Mr. Reali previously served as president and COO of the company. The former CEO will continue to serve the company as the executive chairman of the board of directors, where he will work with Mr. Reali on building shareholder value in the evolving spine market focused on cost-effective minimally invasive surgical therapy.
Mr. Reali is also elected as a member of the board. He has more than 20 years of experience in the medical device industry, including the five years he spent working for Smith & Nephew, Stryker and Biomet.
Read the TranS1 release on Ken Reali.
Read other coverage on TranS1:
– TranS1 Reports 3Q Total Revenues at $6.3M, 8% Decrease
– TranS1 Names Vice President of Research and Development
– TranS1 Releases New System for Lumbar Fusion
